Quantcast

Latest Biogen Idec Stories

2014-03-27 12:30:38

DUBLIN, Mar. 27, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/rwdz5w/therapy_class ) has announced the addition of the "Therapy Class Overview: Rituximab biosimilar" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Approval of Inflectra/Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter! Inflectra is a biosimilar of Johnson & Johnson's Remicade,...

2014-03-27 12:30:26

DUBLIN, Mar. 27, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/fzv3mt/global ) has announced the addition of the "Global Pharmaceutical & Biotechnology Outlook 2014: Mature Biotech" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Positive sentiments for the biotech sector have prevailed in the last two to three years, and the authors expect this trend to continue for the next year too. The optimism is based on...

2014-03-24 12:24:47

Surveyed U.S. Payers Also Seek Improvements from New Agents in Effect on Disability, According to Findings from Decision Resources Group BURLINGTON, Mass., March 24, 2014 /PRNewswire/ -- Decision Resources Group finds that new disease-modifying therapies (DMTs) with improved efficacy in slowing disability progression present the greatest opportunity for drug developers in the treatment of relapsing-remitting multiple sclerosis (RR-MS). This finding is based on the relatively high level of...

2014-03-24 08:28:01

The Approval of ALPROLIX is First Significant Advance in Hemophilia B Treatment in More Than 17 Years CAMBRIDGE, MA, March 24, 2014 /CNW/ - Biogen Idec (NASDAQ: BIIB) has announced that Health Canada approved ALPROLIX((TM) )[Coagulation Factor IX (Recombinant), Fc Fusion Protein], for the control and prevention of bleeding episodes and routine prophylaxis in adults, and children aged 12 and older, with hemophilia B. ALPROLIX is the first approved long-acting hemophilia B therapy and...

2014-03-22 12:21:28

DALLAS, March 22, 2014 /PRNewswire/ -- ReportsnReports.com offers "Global Orphan Drug Market Outlook 2018", "Global Orphan Drugs Market 2014-2018" and "Global Orphan Drug Pipeline Analysis" research reports in its store. The returns on investment from orphan drugs are expected to help the pharma companies to overcome the impact of revenue loss due to expiry of patents of blockbuster drugs. The major drivers for companies to increasingly invest in orphan drugs include...

2014-03-14 20:21:06

NEW YORK, March 14, 2014 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 100, S&P 500, MidCap 400 and S&P SmallCap 600 indices after the close of trading on Friday, March 21: -- S&P 500 constituent Biogen Idec Inc. (NASD:BIIB) will replace S&P 500 constituent American Electric Power Company Inc. (NYSE:AEP) in the S&P 100. Biogen Idec has a market capitalization above $80 billion and is more...

2014-03-12 08:27:11

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, March 12, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Johnson & Johnson (NYSE: JNJ), Express Scripts Inc. (NASDAQ: ESRX), Merck & Co. Inc. (NYSE: MRK), and Forest Laboratories Inc. (NYSE: FRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings...

2014-02-25 23:31:44

Ruth E. Hager is recognized as an NAPW VIP Woman of the Year for her outstanding leadership and commitment within her profession. Garden City, NY (PRWEB) February 25, 2014 NAPW honors Ruth E. Hager as a 2013/2014 Professional Woman of the Year for leadership with this prestigious distinction. As the largest, most-recognized organization of women in the country, spanning virtually every industry and profession, the National Association of Professional Women is a powerfully vibrant...

2014-02-21 16:23:09

On track to initiate Phase 3 study in infants with SMA in the middle of this year CARLSBAD, Calif., Feb. 21, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today provided an update on its ongoing open label, multiple dose Phase 2 study of ISIS-SMN(Rx) in infants with spinal muscular atrophy (SMA). To date, all four infants in the 6 mg cohort have been in the study for over six months and are now approximately nine and a half to 16 months in age with an average age...

2014-02-13 08:30:17

--Isis will receive $9.3 million in milestone payments -- CARLSBAD, Calif., Feb. 13, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that the first child in the 12 mg group was dosed in the ongoing Phase 2 study evaluating ISIS-SMN(Rx) in children with spinal muscular atrophy (SMA). Isis also announced today that the first child was dosed in an open-label extension study, which is being offered to those children with SMA who have completed dosing in...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related